SCOTTSDALE, AZ--(Marketwire - September 23, 2008) - ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announces a collaborative relationship with the University of North Carolina at Charlotte to evaluate ImmuneRegen's Viprovex as a possible cancer-vaccine adjuvant. Adjuvants are agents that stimulate and, subsequently, augment the immune system's response to a foreign antigen.
